Inventaire - your friends and communities are your best library

Current opinion on optimal treatment for colorectal cancer.

author

Eva Segelov

Timothy Price

2000 -

Stephen Ackland

Christos S Karapetis

David Cunningham

Niall Tebbutt

Nick Pavlakis

Michael Jeremy Shapiro

published in: Expert Review of Anticancer Therapy

date of publication: 2013-05-01

main subject: colorectal cancer

Cites articles 69

Date

Title

Authors

2013-02-01

Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy

Timothy Price, Robert T A Padbury
2012-12-10

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial
2012-11-16

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

Josep Tabernero Caturla, David Cunningham, Stephen Clarke, Seock-Ah Im
2012-06-01

Cerebral hemorrhage, warfarin, and intravenous tPA: the real risk is not treating.
2012-09-24

Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

Michael J. Solomon, John Zalcberg
2012-05-23

Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial

Rainer Fietkau, Claus Rödel, Irenaeus A Adamietz, Christian Wittekind, Markus Albertsmeier, Dirk Arnold
2012-10-29

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer

Hennequin Christophe, David Azria, Sophie Gourgou
2012-01-19

A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer
2012-10-25

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

Edward Giovannucci, Jeffrey A Meyerhardt, Charles S. Fuchs, Teppei Morikawa, Katsuhiko Nosho, Shuji Ogino, Paul Lochhead, Reiko Nishihara, Aya Kuchiba, Yoshifumi Baba, Mai Yamauchi, Xiaoyun Liao, Zhi Rong Qian, Ruifang Sun
2012-09-04

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

Eric Van Cutsem, Josep Tabernero Caturla
2012-07-02

Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors

Josep Tabernero Caturla, Christos S Karapetis, Peter Gibbs, Jayesh Desai
2012-06-25

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab

Carsten Bokemeyer
2012-01-10

Curative strategies for liver metastases from colorectal cancer: a review
2012-03-23

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

Claus-Henning Köhne, Eric Van Cutsem, Fortunato Ciardiello, Carsten Bokemeyer
2012-03-01

"Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again?

Robert T A Padbury, Guy J Maddern
2012-11-16

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Eric Van Cutsem, Thierry André, Dirk Arnold, Frank Gieseler
2012-08-28

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Takayuki Yoshino, Atsushi Ohtsu, Taito Esaki, Toshikazu Moriwaki, Tomohiro Nishina, Kentaro Yamazaki, Kensei Yamaguchi, Kei Muro, Akihito Tsuji, Nobuyuki Mizunuma, Naotoshi Sugimoto, Yasushi Tsuji, Chikuma Hamada, Takanori Tanase
2011-08-22

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses
2011-03-07

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer

Josep Tabernero Caturla, Filippo de Braud, Timothy Price
2011-09-06

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

Chris Twelves
2011-03-01

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

John M Ebos
2011-12-14

The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial
2011-09-06

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice

Marc Peeters, Timothy Price
2011-06-05

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Richard Adams, Diether Lambrechts
2011-04-18

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Gunnar Folprecht, Stefano Cascinu, David Cunningham, Fortunato Ciardiello
2011-10-29

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.

Bridget Robinson
2010-05-24

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

Silvia Marsoni, Roberto Labianca, Daniel J. Sargent
2010-09-13

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial

Janet A Dunn, Elaine C Johnstone
2010-10-04

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer

Marc Peeters, Timothy Price, Thierry André
2010-10-27

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

Federica Di Nicolantonio, Andrea Sartore-Bianchi, Alberto Bardelli, Salvatore Siena, Sabine Tejpar, Eric Van Cutsem, Hubert Piessevaux, Sabrina Arena
2010-12-14

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

Nicola Normanno, Fortunato Ciardiello
2010-10-04

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Salvatore Siena, Josep Tabernero Caturla, György Bodoky, David Cunningham, Martin Šmakal, Jacek Jassem

Article - wd:Q38101612

Welcome to Inventaire

the library of your friends and communities

learn more